Wealth Enhancement Advisory Services LLC Purchases 2,591 Shares of DexCom, Inc. (NASDAQ:DXCM)

Wealth Enhancement Advisory Services LLC lifted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 11.4% in the 1st quarter, HoldingsChannel.com reports. The fund owned 25,322 shares of the medical device company’s stock after buying an additional 2,591 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in DexCom were worth $3,512,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DXCM. Advisors Asset Management Inc. boosted its stake in DexCom by 10.8% during the third quarter. Advisors Asset Management Inc. now owns 16,291 shares of the medical device company’s stock worth $1,520,000 after acquiring an additional 1,588 shares in the last quarter. Alps Advisors Inc. increased its position in DexCom by 6.3% in the 3rd quarter. Alps Advisors Inc. now owns 12,877 shares of the medical device company’s stock valued at $1,201,000 after buying an additional 763 shares in the last quarter. Lido Advisors LLC raised its stake in DexCom by 1,485.9% during the 3rd quarter. Lido Advisors LLC now owns 56,298 shares of the medical device company’s stock worth $5,253,000 after buying an additional 52,748 shares during the period. Legacy Advisors LLC boosted its holdings in DexCom by 14.9% in the third quarter. Legacy Advisors LLC now owns 6,584 shares of the medical device company’s stock worth $614,000 after acquiring an additional 852 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. acquired a new stake in DexCom in the third quarter valued at approximately $4,889,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Citigroup upped their target price on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Canaccord Genuity Group lifted their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a report on Friday, April 26th. UBS Group upped their target price on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. Royal Bank of Canada assumed coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target for the company. Finally, Raymond James increased their price objective on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus target price of $140.33.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 49,633 shares of DexCom stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $138.30, for a total value of $6,864,243.90. Following the completion of the sale, the chief executive officer now owns 283,893 shares of the company’s stock, valued at approximately $39,262,401.90. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other DexCom news, CEO Kevin R. Sayer sold 49,633 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the completion of the transaction, the chief executive officer now owns 283,893 shares in the company, valued at $39,262,401.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the sale, the director now directly owns 25,349 shares in the company, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. Insiders have sold a total of 55,735 shares of company stock worth $7,619,347 over the last ninety days. 0.30% of the stock is currently owned by company insiders.

DexCom Price Performance

DXCM opened at $112.49 on Wednesday. DexCom, Inc. has a fifty-two week low of $74.75 and a fifty-two week high of $142.00. The firm has a 50-day moving average of $122.32 and a 200 day moving average of $125.58. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The firm has a market cap of $44.74 billion, a P/E ratio of 72.57, a PEG ratio of 2.77 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.01%. On average, research analysts expect that DexCom, Inc. will post 1.78 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.